Mark Alan  Goldberg net worth and biography

Mark Goldberg Biography and Net Worth

Director of Blueprint Medicines
Mark Goldberg, M.D. has served as a member of our board of directors since June 2015. Dr. Goldberg has served as a member of the board of directors of ImmunoGen, Inc. since November 2011, a member of the board of directors of GlycoMimetics, Inc. since July 2014, a member of the board of directors of Idera Pharmaceuticals, Inc. since March 2014 and a member of the board of directors of Audentes Therapeutics, Inc. since December 2017. Dr. Goldberg served as a member of the board of directors of Synageva Biopharma Corp., or Synageva, from October 2008 until November 2011, when he stepped down to become a member of the executive management team at Synageva. Dr. Goldberg served as a member of the executive management team at Synageva until late 2014, rising to executive vice president, medical and regulatory strategy. In late 2014, Dr. Goldberg stepped down from the executive management team at Synageva and continued to be employed part-time, contributing to medical and regulatory strategy until leaving Synageva in June 2015 upon its acquisition by Alexion Pharmaceuticals, Inc. Prior to joining Synageva, Dr. Goldberg served in various management capacities of increasing responsibility at Genzyme from November 1996 to July 2011, including most recently as senior vice president, clinical development and global therapeutic head, oncology, genetic health, and as chairman of Genzyme’s early product development board. Prior to joining Genzyme, Dr. Goldberg was a full-time staff physician at Brigham and Women’s Hospital and the Dana-Farber Cancer Institute, where he still holds appointments. Dr. Goldberg is a part-time Associate Professor of Medicine at Harvard Medical School and currently serves as acting chief medical officer of CANbridge Life Sciences Ltd., a privately held biopharmaceutical company. Since 2010, Dr. Goldberg has also served as a volunteer on the board of directors of the New England Division of the American Cancer Society. Dr. Goldberg received an A.B. in biochemistry and molecular biology from Harvard University and an M.D. from Harvard Medical

What is Mark Alan Goldberg's net worth?

The estimated net worth of Mark Alan Goldberg is at least $855,352.62 as of December 24th, 2020. Mr. Goldberg owns 9,017 shares of Blueprint Medicines stock worth more than $855,353 as of March 29th. This net worth approximation does not reflect any other assets that Mr. Goldberg may own. Learn More about Mark Alan Goldberg's net worth.

How do I contact Mark Alan Goldberg?

The corporate mailing address for Mr. Goldberg and other Blueprint Medicines executives is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. Blueprint Medicines can also be reached via phone at (617) 374-7580 and via email at [email protected]. Learn More on Mark Alan Goldberg's contact information.

Has Mark Alan Goldberg been buying or selling shares of Blueprint Medicines?

Mark Alan Goldberg has not been actively trading shares of Blueprint Medicines over the course of the past ninety days. Most recently, on Thursday, March 3rd, Mark Alan Goldberg bought 5,000 shares of Blueprint Medicines stock. The stock was acquired at an average cost of $59.98 per share, with a total value of $299,900.00. Learn More on Mark Alan Goldberg's trading history.

Who are Blueprint Medicines' active insiders?

Blueprint Medicines' insider roster includes Jeffrey Albers (CEO), Percy Carter (Insider), George Demetri (Director), Debra Durso-Bumpus (Insider), Mark Goldberg (Director), Kate Haviland (COO), L. Hewes (Insider), Ariel Hurley (Insider), Michael Landsittel (CFO), Nicholas Lydon (Director), Tracey Mccain (EVP), Christopher Murray (Insider), Fouad Namouni (Insider), Christina Rossi (Insider), and Charles Rowland, Jr. (Director). Learn More on Blueprint Medicines' active insiders.

Are insiders buying or selling shares of Blueprint Medicines?

In the last twelve months, insiders at the biotechnology company sold shares 23 times. They sold a total of 167,543 shares worth more than $13,239,414.59. The most recent insider tranaction occured on March, 20th when Director Jeffrey W Albers sold 25,073 shares worth more than $2,188,371.44. Insiders at Blueprint Medicines own 3.9% of the company. Learn More about insider trades at Blueprint Medicines.

Information on this page was last updated on 3/20/2024.

Mark Alan Goldberg Insider Trading History at Blueprint Medicines

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/3/2022Buy5,000$59.98$299,900.00View SEC Filing Icon  
12/24/2020Sell5,455$125.00$681,875.009,017View SEC Filing Icon  
12/1/2020Sell5,454$110.00$599,940.009,016View SEC Filing Icon  
10/7/2020Sell5,454$100.00$545,400.009,016View SEC Filing Icon  
See Full Table

Mark Alan Goldberg Buying and Selling Activity at Blueprint Medicines

This chart shows Mark Alan Goldberg's buying and selling at Blueprint Medicines by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Blueprint Medicines Company Overview

Blueprint Medicines logo
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $94.86
Low: $93.50
High: $95.98

50 Day Range

MA: $86.36
Low: $73.17
High: $99.79

2 Week Range

Now: $94.86
Low: $41.54
High: $101.00

Volume

659,240 shs

Average Volume

814,097 shs

Market Capitalization

$5.81 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.63